Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease

被引：2
作者：
Harskamp R.E. [1 ,2 ]
Park D.-W. [2 ,3 ]
机构：
[1] Academic Medical Center, University of Amsterdam, Amsterdam
[2] Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 27715
[3] Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 138-736, 388-1 Poongnap-dong, Songpa-gu
来源：
Cardiology and Therapy | 2013年 / 2卷 / 1期
关键词：
Coronary artery bypass grafting; Coronary artery disease; Diabetes mellitus; Drug-eluting stents; Percutaneous coronary intervention;
D O I：
10.1007/s40119-013-0014-3
中图分类号：
学科分类号：
摘要：
Patients with diabetes mellitus (DM) are prone to a diffuse and accelerated form of coronary artery disease (CAD), which in turn is a major cause of cardiac-related morbidity and mortality. Compared with patients without diabetes, patients with diabetes undergoing coronary revascularization are at higher risk of procedural, short-, and long-term cardiovascular events and mortality. Although coronary artery bypass grafting (CABG) has been regarded as the primary revascularization strategy in diabetic patients with complex CAD, percutaneous coronary intervention (PCI) is an effective revascularization alternative, due to remarkable advances in stent devices and adjunctive drug therapies. Outcomes data, from subgroup analyses and small-sized clinical trials and large registries, have suggested that PCI with current stent technology showed comparable long-term risks of mortality and hard endpoints, but higher risk of repeat revascularization for the diabetic population compared to CABG. However, the recent landmark International Future REvascularization Evaluation in patients with diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial provides compelling evidence of the superiority of CABG over PCI in reducing the rates of death, myocardial infarction, at the expense of stroke, in patients with diabetes with advanced CAD. When opting for PCI in patients with diabetes, currently used drug-eluting stents (DES) are more efficient in reducing the risk of repeat revascularization without compromising safety outcomes, compared to bare-metal stents. The selection of a specific type of DES in patients with diabetes is controversial and therefore more data comparing second- and newer-generation DES for patients with diabetes are currently needed. Also, efforts to make more advanced DES platforms suitable for patients with diabetes with complicated angiographic features are still ongoing. © 2013 Author(s).
引用
收藏
页码：69 / 84
页数：15
相关论文
共 60 条
  • [1] Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Et al., Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation, 100, pp. 1134-1146, (1999)
  • [2] Hammoud T., Tanguay J.F., Bourassa M.G., Management of coronary artery disease: therapeutic options in patients with diabetes, J Am Coll Cardiol, 3, pp. 355-365, (2000)
  • [3] Roffi M., Angiolillo D.J., Kappetein A.P., Current concepts on coronary revascularization in diabetic patients, Eur Heart J, 32, pp. 2748-2757, (2011)
  • [4] Stefanini G.G., Holmes Jr. D.R., Drug-eluting coronary-artery stents, N Engl J Med., 368, pp. 254-265, (2013)
  • [5] Carson J.L., Scholz P.M., Chen A.Y., Peterson E.D., Gold J., Schneider S.H., Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery, J Am Coll Cardiol, 40, pp. 418-423, (2002)
  • [6] Matsa M., Paz Y., Gurevitch J., Shapira I., Kramer A., Pevny D., Et al., Bilateral skeletonized internal thoracic artery grafts in patients with diabetes mellitus, J Thorac Cardiovasc Surg, 121, pp. 668-674, (2001)
  • [7] Desai N.D., Naylor C.D., Kiss A., Cohen E.A., Feder-Elituv R., Miwa S., Et al., Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial, Circulation, 115, pp. 684-691, (2007)
  • [8] West N.E., Ruygrok P.N., Disco C.M., Webster M.W., Lindeboom W.K., O'Neill W.W., Et al., Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients, Circulation, 109, pp. 867-873, (2004)
  • [9] Mehran R., Dangas G.D., Kobayashi Y., Lansky A.J., Mintz G.S., Aymong E.D., Et al., Short- and long-term results after multivessel stenting in diabetic patients, J Am Coll Cardiol, 43, pp. 1348-1354, (2004)
  • [10] Schofer J., Schluter M., Rau T., Hammer F., Haag N., Mathey D.G., Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study, J Am Coll Cardiol, 35, pp. 1554-1559, (2000)
123456